Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 275 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dextrose solution Clear all
Completed Phase 1Phase 2 Interventional

Joint Injections for Osteoarthritic Knee Pain

NCT00085722
View directory record Official record
Conditions
Osteoarthritis
Interventions
Dextrose Prolotherapy, Saline Prolotherapy, At-home physical therapy exercise group
Procedure · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
40 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 20, 2026, 2:51 AM EDT
Withdrawn Phase 2 Interventional

Mechanisms Underlying Predictors of Success From Obesity Surgery

NCT02697253
View directory record Official record
Conditions
Obesity
Interventions
Exendin 9-39 and Sitagliptin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 20, 2026, 2:51 AM EDT
Completed Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

NCT03834506
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Pembrolizumab, Docetaxel, Prednisone, Placebo, Dexamethasone
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 20, 2026, 2:51 AM EDT
Not listed Phase 2 Interventional

The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes

NCT03426085
View directory record Official record
Conditions
Autonomic Nervous System Diseases, Sweat Gland Diseases, Diabetic Neuropathy With Neurologic Complication
Interventions
Liraglutide 6 mg Solution for Injection, Placebo
Drug · Other
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Oct 20, 2026, 2:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Impact of the Physiological Response to Sugar on Brain Activity and Behavior

NCT06015490
View directory record Official record
Conditions
Food Preferences, Appetitive Behavior
Interventions
Sucrose drink, Glucose drink, Fructose drink
Other
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 20, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers

NCT05159427
View directory record Official record
Conditions
Human Gastrointestinal Physiology Data
Interventions
Glucotrol XL 5Mg Extended-Release Tablet, Glipizide ER 5 MG 24 HR Extended Release Oral Tablet, Rifaximin 200Mg Tab, 13C6-Glipizide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 20, 2026, 2:51 AM EDT
Suspended Phase 1 Interventional

Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

NCT04266730
View directory record Official record
Conditions
Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
PANDA-VAC, Pembrolizumab
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2033
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 20, 2026, 2:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Modulating Glucose Tolerance With Dietary Tyrosine

NCT03872557
View directory record Official record
Conditions
Glucose Tolerance
Interventions
Tyrosine (TYR) Supplementation
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 20, 2026, 2:51 AM EDT
Completed Phase 2 Interventional

Efficacy of Injection Therapy for Lateral Epicondylosis

NCT01476605
View directory record Official record
Conditions
Tennis Elbow
Interventions
Dextrose prolotherapy, PrT-DMS, Platelet Rich Plasma injection
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 20, 2026, 2:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Pulsatile Insulin Secretion (A Study Investigating the Effects of Partial Pacreatectomy on Glucose Metabolism)

NCT00841867
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Oct 20, 2026, 2:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Carbohydrates and Running Performance

NCT06742398
View directory record Official record
Conditions
Nutrition, Healthy
Interventions
Carbohydrate Dissolvable Strip, Carbohydrate Mouth Rinse, Water Mouth Rinse
Other
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 20, 2026, 2:51 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Setrusumab vs Placebo for Osteogenesis Imperfecta

NCT05125809
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Setrusumab, Placebo
Biological · Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
5 Years to 25 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 2:51 AM EDT
Completed Not applicable Interventional

A Pilot Study to Determine Fructose Uptake by Primary Human Colorectal Tumors

NCT05136092
View directory record Official record
Conditions
Colorectal Tumors
Interventions
Cohort 1: HFCS (fructose) fed, Cohort 2: D-Xylose (xylose-fed)
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 20, 2026, 2:51 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Extending Dental Care to Nursing Home Residents to Reduce Mouth Infections and Incidence of Pneumonia and Improve Diabetic Glucose Control

NCT06890676
View directory record Official record
Conditions
Periodontitis, Gingivitis, Periodontal Disease, Periodontal Infections, Oral Infections, Periapical Infections, Pneumonia, Diabetes
Interventions
Comprehensive Oral Evaluation, Intraoral Complete Radiographic Series, • Teledentistry-synchronous and asynchronous, Periodontal Therapy, Periodontal Maintenance Procedure, Application of Caries Arresting Medicament, Oral Hygiene Assistance, Referral for Treatment of Acute Oral Infection
Other · Procedure
Lead sponsor
Missouri Department of Health and Senior Services
Other
Eligibility
60 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jefferson City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 20, 2026, 2:51 AM EDT
Terminated Not applicable Interventional

Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in Infants

NCT01062815
View directory record Official record
Conditions
Cholestasis, Prematurity, Gastroschisis, Intestinal Atresia, Necrotizing Enterocolitis
Interventions
Parenteral Nutrition
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
Up to 7 Days
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 20, 2026, 2:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Food Preservative on Glucose Homeostasis

NCT01179945
View directory record Official record
Conditions
Overweight
Interventions
benzoate containing test drinks, non sodium benzoate containing test drinks
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 20, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

NCT01154621
View directory record Official record
Conditions
Tolerability, Healthy, Elderly
Interventions
AZD9742, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
65 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 20, 2026, 2:51 AM EDT
Completed Phase 3 Interventional

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

NCT04799249
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions
Trilaciclib, Placebo, Gemcitabine, Carboplatin
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 20, 2026, 2:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)

NCT02145247
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
hCG
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 37 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 20, 2026, 2:51 AM EDT
Not yet recruiting Phase 2 Interventional

Amino Acids for Cardiac Surgery Associated AKI

NCT07001098
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Amino Acids, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Day to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 20, 2026, 2:51 AM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 20, 2026, 2:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Evaluation of Balanced Salt Solution During Cataract Surgery

NCT05853978
View directory record Official record
Conditions
Fuchs Dystrophy, Cataract
Interventions
BSS Plus, BSS
Drug
Lead sponsor
Adam Fedyk, MD, FACS
Other
Eligibility
22 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Town and Country, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 20, 2026, 2:51 AM EDT
Completed Phase 4 Interventional

INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

NCT05904743
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Afrezza, insulin degludec, Rapid-acting Insulin Analog, Basal Insulin
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Loma Linda, California • Santa Barbara, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 20, 2026, 2:51 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Study of Thyroid Hormones in Prematures

NCT02103998
View directory record Official record
Conditions
Transient Hypothyroxinemia of Prematurity (THOP)
Interventions
thryoid hormone T4 + oral potassium iodide (KI) for 42 days, D5W - 5% dextrose water
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Hour to 24 Hours
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 20, 2026, 2:51 AM EDT